

Ryvu Therapeutics S.A.
2 Sternbacha Street, 30-394 Krakow, Poland
registered in the District Court for the Krakow-Srodmiescie
in Krakow XI Division of the National Court Register
KRS number: 0000367359
VAT ID: PL6792942955



Krakow, 11th April 2024

#### **REQUEST FOR PROPOSAL No. ABM-11042024A**

In connection with the implementation by Ryvu Therapeutics S.A. of the project "The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent" no. 2022/ABM/06/00002/P/02 (hereinafter: "Project") co-financed from the state budget by the Medical Research Agency under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds no. ABM/2022/6, Ryvu Therapeutics S.A. invites proposals for the execution of the following defined description of the order.

### I. ORDERING PARTY/SPONSOR

Ryvu Therapeutics S.A. Sternbacha 2, 30-394 Krakow, Poland EU VAT PL6792942955

#### II. DESCRIPTION OF THE ORDER

This order concerns the execution of the **CRISPR library sequencing** in the phase II clinical study of a study drug in combination with a market drug in patients with AML.

#### Service description:

- quality control of the DNA material, purity and integrity must be checked on an agarose information on the quality control results in a separate report before deciding on further sample processing;
- preparation of the PCR-free library;
- verification of the library in terms of quality using qPCR, and then checking for fragment length;
- sequencing using NovaSeq6000 S4 PE150 (paired-end 150 bases, Q30≥85% or more) or equivalent [range of equivalence: Sequencing by synthesis (SBS) technology and Patterned flow cell technology], minimum 30Gb of data per library
- Generating a report summarizing the sequencing process, including information about the sequencing method and
  procedure, information about the sequencing process itself, and statistical analysis allowing for the assessment of
  sequencing quality and sample coverage.
- bioinformatic data processing consisting of the following analyses: Quality control of generated data, including
  filtering out low-quality reads and those containing adapter sequences; quality results of obtained readings Q20,
  Q30, distribution of error rate, distribution of GC pairs
- password-protected data delivery via cloud
- ability to track the current order status from personal password-protected account
- the order must be completed without entrusting individual stages of the service to subcontractors
- current information about the progress and stages of work on ordered samples through regular communication with a dedicated project manager.
- technical support and user care provided

Minimum number of samples: 10 Estimated number of samples: 100

Samples delivered in batches, variable number of samples per each batch.

Estimated number of batches: 6.

## II.2. Rules of order execution

- CONTRACT TERM: Deadline for performance of the contract: 31<sup>st</sup> May 2024.
   In the event of prolonging the completion date of the Project stage, the agreement may be extended following changes in the Project co-financing agreement.
- **OFFER VALIDITY PERIOD**: at least until 30<sup>st</sup> April 2024.
- ORDER COMPLETION DATE (TURNAROUND TIME): up to 21 calendar days after QC decisions.

  The execution of orders under the contract must take place within max. period given below. The turnaround time is an <u>admission condition</u>, proposal indicating a longer deadline for performance will be rejected.

• Bidders have to be able to demonstrate compliance quality standards required for the handling and sample analysis: **EMQN and ISO 17025** lab or equivalent certificates.

### III. PLACE, DATE PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

- III.1. The proposal must be submitted by: 18<sup>th</sup> April 2024.
- **III.2.** The proposal must be sent via e-mail to the following address: <u>tenders@ryvu.com</u>. The message with the proposal should refer to the RFP number indicated on the first page: <u>ABM-11042024A</u>.
- **III.3.** The proposal and its attachments must be prepared in English or Polish.
- III.4. The proposal should be prepared in an accordance with the form constituting Appendix 01 to this RFP.

  The Bidders must provide the price for the service for 1 sample and the price the execution of the scope of the contract (total price for service for 100 samples).

### IV. ADDITIONAL INFORMATION

- **IV.1.** The Ordering Party allows for the possibility of awarding to the Contractor supplementary orders, in an amount not exceeding 50% of the value of the contract specified in the agreement concluded with the contractor, while such orders are consistent with the subject of the basic contract.
- **IV.2.** The terms and conditions of the agreement may change during the course of the agreement (Ordering Party reserves the right to amend the agreement):
  - in terms of the timelines and term of the agreement following changes in the scope of the study and Project (extension of the duration of the Project, extension of appropriate stages of the Project, change of research plans);
  - in the event of force majeure as an event which is externally impossible to foresee and which could not have been prevented and whose consequences and effects could not have been prevented.
- **IV.3.** The Bidders may ask the Ordering Party to clarify the content of the RFP. If the request for clarification of the content of the RFP was received later than by the end of 15<sup>th</sup> April 2024, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: <a href="mailto:tenders@ryvu.com">tenders@ryvu.com</a>.
- **IV.4.** The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.
- IV.5. Whenever the Ordering Party uses trademarks/brands/standards/manufacturer's names in the documentation, it shall be assumed that the wording "or equivalent" is used in reference to them, thus it is acceptable to submit a tender indicating an equivalent subject matter of the contract to that described by the Ordering Party. The indications in relation to the expected technical parameters, as well as the indications in relation to specific types and manufacturers' names are of a general nature, referring only to exemplary indications of equivalent products and do not constitute the only acceptable solution. On this basis, the Ordering Party accepts equivalent solutions. A contractor who submits an equivalent offer is obliged to prove, under pain of rejection of the offer, that the submitted offer is equivalent to the one described by the Ordering Party.
- **IV.6.** The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of proposals for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the proposal sent by the Bidder.
- **IV.7.** This RFP serves to estimate the market price of the contract (of 100 samples to be entirely tested). The Ordering Party reserves the right to enter into negotiations with Bidders who have submitted a proposal and meets the conditions for participating in the proceedings. Arrangements regarding the date of negotiations will be carried out by e-mail. The modified proposal may not contain conditions less favorable than the original proposal.
- IV.8. This RFP does not oblige the Ordering Party to conclude a contract.
- IV.9. For more information, please contact Anna Dziedzicka at the following email address: tenders@ryvu.com.

## **ATTACHMENTS**

Appendix 01 – Proposal Form

# APPENDIX 01 TO RFP no. ABM-11042024A

# THE PROPOSAL FORM

| Data of the Bidder                               |  |  |  |  |
|--|--|--|--|--|
| Name:  |  |  |  |  |
| Address:   |  |  |  |  |
| Tax ID/EU VAT:                                   |  |  |  |  |
| Person authorized to contact the Ordering Party: |  |  |  |  |
| name and surname:                                |  |  |  |  |
| e-mail address:                                  |  |  |  |  |

|   | Answer / confirmation of |                  |
|---|--------------------------|------------------|
|   | compliance               | Comments, if any |
| Service description:  | *- delete inappropriate  |                  |
| quality control of the DNA material, purity and   |                          |                  |
| integrity must be checked on an agarose -   |                          |                  |
| information on the quality control results in a   |                          |                  |
| separate report before deciding on further  |                          |                  |
| sample processing;  |                          |                  |
| <ul> <li>preparation of the PCR-free library;</li> </ul>  |                          |                  |
| verification of the library in terms of quality   |                          |                  |
| using qPCR, and then checking for fragment  |                          |                  |
| length;   |                          |                  |
| <ul> <li>sequencing using NovaSeq6000 S4 PE150</li> </ul>   |                          |                  |
| (paired-end 150 bases, Q30≥85% or more) or  |                          |                  |
| equivalent [range of equivalence: Sequencing by   |                          |                  |
| synthesis (SBS) technology and Patterned flow   |                          |                  |
| cell technology], minimum 30Gb of data per  |                          |                  |
| library   |                          |                  |
| <ul> <li>Generating a report summarizing the</li> </ul>   |                          |                  |
| sequencing process, including information   |                          |                  |
| about the sequencing method and procedure,  |                          |                  |
| information about the sequencing process itself,  |                          |                  |
| and statistical analysis allowing for the   | YES/NO*                  |                  |
| assessment of sequencing quality and sample   |                          |                  |
| coverage.   |                          |                  |
| bioinformatic data processing consisting of the  following analyses Overline system of the syst |                          |                  |
| following analyses: Quality control of generated  |                          |                  |
| data, including filtering out low-quality reads and those containing adapter sequences; quality   |                          |                  |
| results of obtained readings Q20, Q30,  |                          |                  |
| distribution of error rate, distribution of GC  |                          |                  |
| pairs   |                          |                  |
| password-protected data delivery via cloud  |                          |                  |
| ability to track the current order status from  |                          |                  |
| personal password-protected account   |                          |                  |
| the order must be completed without   |                          |                  |
| entrusting individual stages of the service to  |                          |                  |
| subcontractors  |                          |                  |
| current information about the progress and  |                          |                  |
| stages of work on ordered samples through   |                          |                  |
| regular communication with a dedicated project  |                          |                  |
| manager.  |                          |                  |
| <ul> <li>technical support and user care provided</li> </ul>  |                          |                  |
| CONTRACT TERM: Deadline for performance of the  |                          |                  |
| ontract: 31 <sup>st</sup> May 2024.   |                          |                  |
| n the event of prolonging the completion date of the  | YES/NO*                  |                  |
| Project stage, the agreement may be extended following  |                          |                  |
| changes in the Project co-financing agreement.  |                          |                  |

| <b>OFFER VALIDITY PERIOD</b> : at least until 30 <sup>th</sup> April 2024.   | YES/NO* |  |
|--|---------|--|
| ORDER COMPLETION DATE (TURNAROUND TIME): up to 21 calendar days after QC decisions.  The execution of orders under the contract must take place within max. period given below. The turnaround time is an admission condition, proposal indicating a longer deadline for performance will be rejected. | YES/NO* |  |
| Bidder is be able to demonstrate compliance quality standards required for the handling and sample analysis: EMQN and ISO 17025 lab or equivalent certificates.  | YES/NO* |  |
| of performing <u>one experiment</u> includir   |         |  |
| of performing QC for 1 sample – only (price if Ordering P  |         |  |
| passwo<br>the price for data delivery via cloud may be charge  |         |  |
| of performing 100 experiments + 6 x data delivery via<br>= estimated value of the contract tha   |         |  |

We confirm that the scope of the service offered is consistent with the subject of the request of the RFP no. ABM-11042024A.

Place and date Signature of the authorized person